Interaction of CYP2C19,P2Y12,and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke

Abstract

Objective:

Clopidogrel is a clinically important oral antiplatelet agent for the treatment or prevention of cerebrovascular disease. However, different individuals have different sensitivities to clopidogrel. This study assessed variants of different genes for association with response to clopidogrel, clinical outcome, and side effects in patients with ischemic stroke (IS).

Methods:

We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [P2Y12, P2Y1)], and glycoprotein IIIa [GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up.

Results:

Adverse events occurred in 37 patients (31 had IS recurrence, 4 died, and 2 had myocardial infarction) during the first 6 months of follow-up. Single locus analysis showed that only the CYP2C19*2(rs4244285) variant was independently associated with CS and risk of adverse events after adjusting covariates. However, there was significant gene–gene interaction among CYP2C19*2(rs4244285), P2Y12(rs16863323), and GPIIIa (rs2317676) analyzed by generalized multifactor dimensionality reduction methods. The rate of adverse events among patients with the 3-loci interaction was 2.82 times the rate among those with no interaction (95% confidence interval: 2.04-8.63).

Conclusion:

Sensitivity of patients with IS to clopidogrel and clopidogrel-induced adverse clinical events may be multifactorial but is not determined by single gene polymorphisms.

Keywords

ischemic stroke clopidogrel resistance genetic variants stroke outcome

Introduction

Stroke is a significant worldwide health problem and is one of the leading causes of death among the elderly individuals.¹ Patients with an ischemic stroke (IS) are also at a high risk of developing a recurrent stroke. To date, antiplatelet therapy using aspirin or clopidogrel is highly recommended for these patients.^2,3 A previous study demonstrated that clopidogrel was shown to be superior to aspirin to reduce the risk of IS.⁴ However, a proportion of patients receiving clopidogrel treatment did experience recurrent ischemic stroke (RIS) or other vascular events,⁵ referred to as clopidogrel resistance (CR), that is, poor or no response to clopidogrel treatment.⁶ Several other studies also showed that reduced response to clopidogrel occurred in 4.8% to 51% of such patients.^7,8 This high variance can partially be attributed to the variability in study design and poor comparability among different measurement techniques, but genetic variants may also be responsible. However, the underlying mechanisms leading to a poor response to clopidogrel therapy have not yet been fully elucidated and are most likely multifactorial. For example, patient compliance, absorption or metabolic dysfunction, drug interactions, diabetes, or hypertension may influence the response to clopidogrel.⁹ Thus, the genetic etiology of CR has also been proposed.¹⁰

Clopidogrel is a prodrug requiring intestinal absorption and metabolic activation in the liver, then irreversibly blocking the binding of adenosine diphosphate (ADP) to the platelet P2Y12 receptor, which in turn prevents the inactivation of adenylate cyclase and the subsequent activation of the glycoprotein GPIIb/IIIa complex that is required for platelet aggregation.^11,12 There is growing evidence showing that clopidogrel sensitivity (CS) may be influenced by pharmacokinetic variables, such as intestinal absorption, metabolic activation in the liver, platelet P2Y12 receptor, and glycoprotein GPIIb/IIIa, all of which are further affected by gene polymorphisms.^{13

–25} Individual variations may be caused by genetic variants of genes that respond to drug absorption (ATP binding cassette transporter B1, ABCB1), metabolic activation (cytochrome P450 [CYP] 3A and CYP2C19), and biologic activity (platelet membranes receptor [P2Y12, P2Y1], and glycoprotein IIIa [GPIIIa]). Previous studies showed inconsistent data for these factors with CS. ABCB1, CYP3A5, P2Y12, and PlA1/A2 polymorphisms were not associated with CR,^25

–28 indicating that the genetic factors for CR may be very complex; it may be that genetic variants at individual loci only contribute to CR by interaction with other gene variants. Moreover, the effects of individual locus alone on CR may be too small to be observed. Thus, the investigation of multiple gene–gene interactions is necessary to be able to understand the genetic basis of CR risk in patients with IS using alternative analytical methods, such as the generalized multifactor dimensionality reduction (GMDR) approach.²⁹ Currently, there is no such publication of the potential effects of gene–gene interactions on CR risk. We, therefore, hypothesized that relevant genetic variants and interaction among these variants may contribute to CR and cause a higher rate of ischemic events in patients with IS after treatment with clopidogrel. To test this, we assessed previously identified polymorphisms of genes modulating clopidogrel absorption (ABCB1), metabolic activation (CYP3A5, CYP3A4, and CYP2C19), and biological activity (P2Y12, P2Y1, and GPIIIa), as well as their interactions, for association with CR and ischemic events or death during the first 6 months follow-up period in patients with IS after treatment with clopidogrel. This study was expected to provide novel insight into the mechanism of CR.

Materials and Methods

Ethical Statement

A protocol for this prospective study was reviewed and approved by the Ethics Committees of The People’s Hospital of Deyang City and The Third Affiliated Hospital of Wenzhou Medical College. Written informed consent was obtained from each participant before they were enrolled into this study.

Study Population

We consecutively enrolled 375 patients with IS with first-time stroke from these 2 hospitals between June 2014 and January 2015. These patients had IS within 72 hours and were treated with clopidogrel. The inclusion criteria were as follows: (1) Patients were ≥40 years of age; (2) patients had IS-related atherothrombotic or small artery disease according to the Trial of Org 10172 in Acute Stroke Treatment classification system³⁰; (3) patients had not taken clopidogrel for at least 7 days before admission; and (4) patients had a National Institutes of Health Stroke Scale (NIHSS) score <15.The exclusion criteria were (1) individuals who declined to participate in this study; (2)patients had an allergy to clopidogrel; (3) patients had cardiac cerebral embolism or any other determined or undetermined etiology of IS; (4) patients had undergone thrombolytic or anticoagulation therapy with warfarin or heparin within 7 days; (5) patients had received a proton pump inhibitor before or during hospital admission; (6) patients had hemorrhagic stroke, hematological diseases, autoimmune diseases, or other severe concomitant diseases; and (7) patients had a platelet count < 1 × 10¹¹/L or > 4.5 × 10¹¹/L.

All patients received standard therapies based on standard guidelines of treatment protocol,² that is, 75 mg clopidogrel (Sanofi Company Ltd., Beijing, China) once daily or clopidogrel (75 mg, once daily) plus aspirin (200 mg, once daily; Bayer Healthcare Company Ltd., Beijing, China), for the initial 2 weeks in patients with minor stroke (NIHSS score ≤ 3) or symptomatic carotid or intracranial artery stenosis, followed by treatment with clopidogrel alone (75 mg, once daily) for at least 6 months. Data on various risk factors, including body mass index, body weight, current smoking, diabetes mellitus, and hypertension were recorded; fasting blood samples were assessed for blood sugar, total plasma cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and homocysteine.

Adenosine Diphosphate-Induced Platelet Aggregation Assay

All patients were subjected to ADP-induced platelet aggregation assay before and after 7 to 10 days of clopidogrel administration. Platelet aggregation level was measured by light transmittance aggregometry. The procedure and the consistency were assessed according to our previous studies.^31,32 In brief, 5 mL of the fasting venous blood were collected in 660 μL of 3.8% sodium citrate and centrifuged at 200×g for 10 minutes to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained from the remaining specimens by centrifugation at 4000×g for 10 minutes. The platelet aggregation test was performed using ADP (Helena Laboratories, Beaumont, Texas) at 10.0 μmol/L and measured by the light transmittance aggregometry with a BioData PAPS-4 platelet aggregometer (Helena Laboratories). Platelet aggregation rate was recorded as change in the light transmission. The recorder was adjusted to make sure that the difference in light transmission between PRP and PPP was 100%. The results were presented as the amplitude of light transmittance at 5 minutes after addition of 10.0 μmol/L ADP agonist. Clopidogrel resistance was defined as a reduction of <10% in 10.0 μmol/L ADP-induced platelet aggregation after 7 to 10 days of clopidogrel treatment^7,8; otherwise, it was considered as CS.

Selection and Genotyping of Single-Nucleotide Polymorphism

In this study, we selected a total of 12 single-nucleotide polymorphisms (SNPs) of relevant genes, including ABCB1(rs2032562), CYP3A5(rs776746), CYP3A4(rs2242480), CYP2C19*2(rs4244285), CYP2C19*3(rs4986893), P2Y12(rs16863323, and rs9859538), P2Y1(rs701265, rs1439010, and rs1371097) and GPIIIa (rs2317676 and rs11871251) from the NCBI database (http://www.ncbi.nlm.nih.gov/SNP). The inclusion criteria were: (1) SNPs that had been assessed in previous studies^{13

–28}; (2) SNPs with minor allele frequency >0.05; and (3) SNPs that had been tagged across different human populations (http://pga.gs.washington.edu).

The genotyping of these SNPs was performed in genomic DNA extracted from periphery blood samples using the matrix-assisted laser desorption/ionization time of flight mass spectrometry method according to our previous studies.^33,34 Each SNP was amplified using 2 specific polymerase chain reaction (PCR) primers and 1 extension primer (Table S1). Genotype call was performed in real time with Mass ARRAY RT software version 3.0.0.4 and analyzed using Mass ARRAY Typer software, version 3.4 (Sequenom Inc., San Diego, CA).

Each allele of these CYP SNPs was classified by its known effect on enzymatic function according to the literature and with the use of established common consensus star allele nomenclature.^35
–37 For each gene, patients were dichotomized a priori into 2 groups based on whether they possessed at least 1 allele with a significantly reduced function.

Assessment of Clinical Outcome

Follow-up for each patient took place every month at our outpatient clinic for a period of 6 months. Drug compliance was monitored during outpatient visits or via telephone interview. Clinical data were collected from patients’ medical records or via phone interview by the referring physicians.

The primary adverse outcome of clopidogrel treatment was a composite of recurrent ischemic stroke (RIS), myocardial infarction (MI), and death during the first 6 months. Recurrent ischemic stroke was defined as a new focal neurologic deficit of vascular origin lasting for at least 24 hours, which was proved to be nonhemorrhagic by either computed tomography or magnetic resonance imaging scanning. Death was defined as vascular mortality due to MI, IS, and other vascular causes. Side effects included hemorrhagic episodes occurred within 6 months after treatment and the later was defined as the presence of any of the following: (1) symptomatic or asymptomatic hemorrhagic transformation (HT), symptomatic or asymptomatic intracerebral hemorrhage (ICH) and (2) extracranial hemorrhages (eg gastrointestinal bleeding, hematoma, hematuria, and skin or mucosal bleeding). Serious hemorrhage was considered as any symptomatic intracranial hemorrhage or any hemorrhage requiring blood transfusion or prolonged hospitalization.

Statistical Analysis

A χ² test was performed to analyze the deviation of Hardy-Weinberg equilibrium for genotype frequencies and to compare genotype frequencies. Continuous variables were analyzed using Student t test. Discrete variables were assessed using the χ² test or Fisher exact test. Gene–gene interaction was assessed using the GMDR program (beta version 0.7; www.healthsystem.virginia.edu/internet/addiction-genomics/Software).²⁹

A significant independent predictor of CR was analyzed using a logistic regression analysis. The relative risk of a genotype with CR was expressed using odds ratio (OR) with a 95% confidence interval (CI). The Cox proportional hazards model was used to describe the risk of primary efficacy outcome and reported as values of the hazard ratio (HR) with 95% CI. All statistical analyses were performed using SPSS 16.0 (SPSS Inc, Chicago, Illinois), and all tests were 2 sided. A P value ≤ .05 was considered statistically significant.

Results

Characteristics of Patients

Among 375 patients with IS, 153 (40.8%) showed CR, whereas 222 (59.2%) showed CS. Clopidogrel resistance was significantly associated with greater age (P = .013), diabetes mellitus (P < .001), and higher fasting plasma glucose levels (P < .001; Table 1). There was no significant difference in other factors between these 2 groups of patients (all P > .05, Table 1). Furthermore, there was no significant difference in incidence of CR between patients receiving clopidogrel alone and those taking clopidogrel plus aspirin (Table 1), and there was also no significant difference in the inhibition of platelet aggregation between patients on clopidogrel alone and those taking clopidogrel plus aspirin (39.86% ± 10.87% vs 41.26% ± 11.58%, P = .87). This indicated that aspirin does not have an effect on the ADP-induced platelet aggregation.

Table 1.

Baseline Characteristics of Patients With Ischemic Stroke.

	CR Group (n = 153)	CS Group (n = 222)	P Value
Age, years	69.97 ± 11.23	67.04 ± 12.16	.013
Male, n (%)	99 (64.86)	143 (64.42)	.98
Hypertension, n (%)	121 (79.08)	172 (77.48)	.67
Diabetes mellitus, n (%)	80 (52.29)	77 (34.68)	<.001
Current smoker, n (%)	64 (41.83)	94 (42.34)	.86
Body mass index, kg/m²	23.99 ± 3.11	23.96 ± 3.18	.98
Previous MI, n (%)	8 (5.23)	10 (4.50)	.78
Alcohol intake, n (%)	67 (43.79)	94 (42.34)	.83
TG, mmol/L	1.54 ± 0.53	1.56 ± 0.64	.96
TC, mmol/L	5.52 ± 1.35	5.48 ± 1.38	.87
LDL-C, mmol/L	2.98 ± 0.96	2.94 ± 0.92	.95
HDL-C, mmol/L	1.23 ± 0.36	1.25 ± 0.44	.93
Fasting plasma glucose, mmol/L	7.78 ± 2.44	6.68 ± 2.31	<.001
Hcy, mmol/L	14.52 ± 4.27	14.58 ± 4.45	.89
HbA1c, %	6.27 ± 1.58	6.19 ± 1.61	.76
Admission NIHSS	5.93 ± 1.82	5.86 ± 1.91	.45
Stroke subtype
Atherothrombotic, n (%)	94 (61.44)	137 (61.71)	.88
Small artery disease, n (%)	57 (37.25)	87 (39.19)	.88
Previous treatment, n (%)
Antihypertensive drugs	66 (43.14)	97 (43.69)	.92
Hypoglycemic drugs	57 (37.25)	83 (37.39)	.94
Statins	26 (16.99)	38 (17.12)	.89
Aspirin	42 (27.45)	63 (28.39)	.77
In-hospital treatment, n (%)
Antihypertensive drugs	132 (86.27)	190 (85.59)	.86
Hypoglycemic drugs	21 (56.76)	175 (53.68)	.28
Statins	150 (98.04)	219 (98.65)	.79
Clopidogrel plus aspirin	95 (62.09)	136 (61.26)	.65
Clopidogrel alone	58 (37.91)	86 (38.74)	.65

Abbreviations: CR, clopidogrel resistance; CS, clopidogrel sensitivity; MI, myocardial infarction; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; HbA1c, Hemoglobin A1C; Hcy, Homocysteine; NIHSS, National Institutes of Health Stroke Scale.

Allelic Frequency, Gene–Gene Interaction, and Association With CR

The genotype distributions of these 12 genetic variants were in Hardy-Weinberg equilibrium. The allelic frequencies of rs701265, rs1439010, rs1371097, rs776746, rs4244285, rs16863323, rs2317676, and rs11871251 differed significantly between patients with and without CR (Table 2). However, only the CYP2C19*2 (rs4244285) variant was independently associated with CR after adjusting covariates (OR = 1.96, 95%CI: 1.23-4.17, P = .018).

Table 2.

Association of SNPs With Responses of Clopidogrel Treatment in Patients With IS, n (%).

	CR Group (n = 153)	CS Group (n = 222)	P Value
CYP3A4(rs2242480)			.91
CC	83(54.2)	123(55.4)
TT+CT	70(45.8)	99(44.6)
ABCB1(rs2032562)			.74
GG	38(24.8)	52(23.4)
TT + GT	115(75.2)	170(76.7)
P2Y1(rs701265)			.032
AA	73(47.7)	131(59.0)
AG+GG	80(52.3)	91(41.0)
P2Y1(rs1439010)			.041
AA	73(47.7)	131(59.0)
AG+GG	80(52.3)	91(41.0)
P2Y1(rs1371097)
CC	73(47.7)	133(59.9)	.019
TT+CT	80(52.3)	89(40.1)
CYP3A5(rs776746)
AA	12(7.8)	36(16.2)	.016
GG+AG	141 (92.2)	186 (83.8)
CYP2C192*(rs4244285)			<.001
GG	46(30.1)	107(48.2)
AG+AA	107(69.9)	115(51.8)
CYP2C193*(rs4986893)
GG	139(90.8)	209(94.1)	.24
AG	14(9.2)	13(5.9)
P2Y12(rs16863323)			.004
CC	21(13.7)	57(25.7)
TT+CT	132(86.3)	165(74.3)
P2Y12(rs9859538)			.157
GG	106(69.3)	168(75.7)
AG+AA	47(30.7)	54(24.3)
GPIIIa (rs2317676)			.036
AA	92(60.1)	158(71.2)
AG+GG	61(39.9)	64(28.8)
GPIIIa (rs11871251)			.042
AA	55(35.9)	58(26.1)
AG+GG	98(64.1)	164(73.9)

Abbreviations: SNPs, single nucleotide polymorphisms; IS, ischemic stroke; CR, clopidogrel resistance; CS, clopidogrel sensitivity.

We then assessed the association of the high-order interactions of SNPs with CR using the GMDR method. After being adjusted with covariates, the best model for CR included rs4244285, rs16863323, and rs2317676, which scored10 of 10 for cross-validation consistency and 9 of 10 for the sign test (P = .013), suggesting that these 3 genetic variants together significantly contributed to CR. Specifically, compared to patients harboring rs4244285GG, rs16863323CC, and rs2317676AA (all wild-type genotypes), the 3 gene interactions making the largest contributions to this model were those occurring among rs4244285AA, rs16863323TT, and rs2317676GG (OR = 2.65, 95%CI: 1.21-6.82, P = .006); rs4244285AA, rs16863323CT, and rs2317676AG(OR = 2.32, 95%CI: 1.16-5.26, P = .023); and rs4244285AA, rs16863323TT, and rs2317676AG/GG (OR = 1.88, 95% CI: 1.03-3.92, P =.042; Table 3). These data suggest that these 3 genetic variants together significantly contributed to CR in patients with IS.

Table 3.

Associations Between Cerebral Infarction and Genotype Combinations.

rs4244285	GG	AA	AA	AA	AG	AA, AG	AA	AA, AG
rs16863323	CC	TT	TT	CT	CT	TT	TT, CT	TT, CT
rs2317676	AA	GG	AG, GG	AG	AG	GG	GG	GG, AG
OR	1^a	2.65	1.88	2.32	1.24	1.09	1.17	1.08
95% CI	–	1.21-6.82	1.03-3.92	1.16-5.26	0.86-2.47	0.63 -1.94	0.65-2.11	0.65 -1.83
P value	–	.006	.042	.023	.32	.26	.53	.63

Abbreviations: OR, odds ratio; CI, confidence interval.

^aThe low-risk genotype for each genetic factor was used as the reference.

Major Adverse Events in Patients With IS After Clopidogrel Treatment

Among these 375 patients treated with clopidogrel, 363 completed a 6-month follow-up; 149 (97.4%) of 153 patients showed CR, and 214 (96.4%) of 222 patients showed CS. Primary adverse events occurred in 37 patients (31 had RIS, 4 died, and 2 had MI) during the first 6-month follow-up. Clinically, patients with adverse events were older and had a higher prevalence of diabetes mellitus (Table 4). There was also a higher rate of adverse events in patients carrying the rs4244285 variant allele (genotype AA or AG) than in those with the wild-type allele (genotype GG). There was a higher rate of adverse events in patients carrying the rs776746 variant allele (genotype GG or AG) than in those with the wild-type allele (genotype AA). High-risk interactive genotypes (rs4244285, rs16863323, and rs2317676) were also associated with a higher rate of adverse events compared to genotypes with no such interaction (Table 4). The frequency of primary adverse effects and RIS was higher in patients after CR than those with CS (Table 5). There was no significant difference in the rate of extracranial hemorrhage, asymptomatic ICH, and asymptomatic HT between the CR and the CS groups (Table 5). There were no serious hemorrhage, symptomatic HT, or symptomatic ICH events observed in either of the 2 groups of patients.

Table 4.

Characteristics of Patients With or Without Adverse Events.^a

	Patients With Adverse Events (n = 37)	Patients Without Adverse Events (n = 326)	P Value
Age, year	69.96 ± 10.98	67.03 ± 12.26	.01
Men, n (%)	24 (64.86)	210 (64.42)	.99
Diabetes mellitus, n (%)	20 (54.05)	133 (40.79)	.01
Hypertension, n (%)	31 (83.78)	257 (78.83)	.74
Body mass index, kg/m²	24.05 ± 3.12	23.92 ± 3.29	.88
Current smoker, n (%)	16 (43.24)	136 (41.72)	.76
Alcohol intake, n (%)	16 (43.24)	140 (42.94)	.82
Previous MI, n (%)	2 (5.41)	15 (4.60)	.72
TG, mmol/L	1.53 ± 0.56	1.57 ± 0.67	.58
TC, mmol/L	5.53 ± 1.33	5.39 ± 1.28	.25
LDL-C, mmol/L	3.01 ± 0.97	2.97 ± 0.99	.31
HDL-C, mmol/L	1.22 ± 0.43	1.24 ± 0.48	.97
Hcy, mmol/L	14.46 ± 3.98	14.59 ± 4.68	.22
Fasting blood glucose, mmol/L	7.11 ± 2.68	6.89 ± 2.42	.28
HbA1c, %	6.36 ± 1.39	6.17 ± 1.56	.15
Admission NIHSS	5.96 ± 1.87	5.85 ± 1.84	.16
Stroke subtype
Atherothrombotic, n (%)	23 (62.16)	200 (61.35)	.72
Small artery disease, n (%)	14 (37.84)	126 (38.65)	.72
In-hospital treatment, n (%)
Antihypertensive drugs	32 (86.49)	279 (85.58)	.71
Hypoglycemic drugs	21 (56.76)	175 (53.68)	.23
Statins	36 (97.29)	318 (97.55)	.91
Clopidogrel plus aspirin	23 (62.16)	199 (61.04)	.58
Rs776746
AA(n = 45)	0 (0.0)	45 (13.80)	.018
GG+AG(n = 318)	37 (100.0)	281 (86.20)
Rs4244285
GG (n = 148)	7 (18.92)	141 (43.25)	.003
AG+AA (n = 215)	30 (81.08)	185 (56.75)
Interactive genotypes of rs4244285, rs16863323, and rs2317676
Yes (n = 108)	35 (94.59)	73 (22.39)	<.001
No (n = 255)	2 (5.41)	253 (77.61)

Abbreviations: MI, myocardial infarction; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; HbA1c, Hemoglobin A1C; Hcy, Homocysteine; CR, clopidogrel resistance; CS, clopidogrel sensitive.

^aInteractive genotypes include rs4244285AA, rs16863323TT, and rs2317676GG or rs4244285AA, rs16863323CT, and rs2317676AG or rs4244285AA, rs16863323TT, and rs2317676AG/GG.

Table 5.

Association of CR With its Adverse Clinical Outcomes.

	CR Group (n = 149)	CS Group (n = 214)	P Value
The primary adverse outcome, n (%)	23 (15.4)	14 (6.5)	.023
RIS, n (%)	20 (13.4)	11 (5.1)	.021
MI, n (%)	1 (0.7)	1 (0.5)	.83
Death, n (%)	2 (1.3)	2 (0.9)	.82
Safety outcomes
Asymptomatic HT, n (%)	3 (2.0)	4 (1.9)	.92
Asymptomatic ICH, n (%)	1 (0.7)	1 (0.5)	.86
Extracranial bleeding, n (%)	3 (2.0)	5 (2.3)	.85

Abbreviations: CR, clopidogrel resistant; CS, clopidogrel sensitive; RIS, recurrent ischemic stroke; MI, myocardial infarction; mRS, modified Rankin Scale, HT, hemorrhagic transformation; ICH, intracranial hemorrhage.

Furthermore, Cox regression analysis revealed that diabetes mellitus (HR = 1.66, 95%CI: 1.12-3.84, P = .021), CR (HR = 1.86, 95%CI: 1.08-3.24, P = .042), rs4244285 (HR = 1.898, 95%CI: 1.28-6.25, P = .004), and the interactive variables of rs4244285, rs16863323, and rs2317676 (HR = 2.82, 95%CI: 2.04-8.63, P < .001) were independent risk predictors for these primary adverse events occurring (Table 6).

Table 6.

Cox Regression Analysis of Independent Predictors for Adverse Events.^a

Factor	HR	95% CI	P Value
Hypertension	1.23	0.92-3.08	.068
Diabetes mellitus	1.66	1.12-3.84	.021
Clopidogrel plus aspirin	1.24	0.98-3.24	.056
CR	1.86	1.08-3.24	.042
Rs4244285	1.98	1.28-6.25	.004
Interactive variable	2.82	2.04-8.63	<.001

Abbreviations: HR, hazard ratio; CI, confidence interval; CR, Clopidogrel resistant.

^aInput variables include age, gender, tobacco smoking, hypertension, diabetes mellitus, stroke subtype, body mass index, previous myocardial infarction, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, triglycerides, hemoglobin A1C, Clopidogrel plus aspirin, homocysteine, rs4244285, rs16863323, rs2317676, rs11871251, rs776746, rs1371097, rs701265, rs1439010, rs2242480, rs9859538, rs4986893, rs2032562, and the interactive variable of rs4244285, rs16863323, and rs2317676.

Discussion

In the current study, we analyzed different gene variants in blood samples from patients with IS having received clopidogrel therapy for their association with CS and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up. Our data showed that there were 37 patients with adverse events: Single locus analysis showed that the variant CYP2C19*2(rs4244285) was independently associated with CS and risk of adverse events after adjusting covariates. Moreover, there was significant gene–gene interaction among CYP2C19*2(rs4244285), P2Y12 (rs16863323), and GPIIIa (rs2317676). Thus, the sensitivity of patients with IS to clopidogrel and adverse clinical events maybe multifactorial. Future study is needed to further identify how gene–gene interactions manipulate or modify CS, adverse events, and the outcome of treatment.

Indeed, clopidogrel is a prodrug, and in order to become active, it must be metabolized in the liver by several CYP enzymes, including CYP3A and CYP2C19.³⁸ A previous study showed that CYP3A5*3 variant alleles and genotypes were significantly associated with CR.³⁹ Moreover, Suh et al¹⁷ also revealed that CYP3A5 nonexpression genotype (CYP3A5*3) was associated with an increased frequency of atherothrombotic events within 6 months after coronary angioplasty in patients, whereas other studies did not confirm any association between CYP3A5 genetic variants and the antiplatelet effect of clopidogrel.^10,40 Likewise, the results of the present study do not support the association of the CYP3A5 genetic polymorphism with a clinical response to clopidogrel. However, genetic polymorphisms of CYP2C19 were able to modulate clopidogrel pharmacokinetics and pharmacodynamics.¹⁸ Previous studies demonstrated that carriers with ≥1 genetic variant of CYP2C19 alleles (2* or 3*) were associated with a significantly lower plasma level of clopidogrel-active metabolite and reduced antiplatelet effect of clopidogrel, using ex vivo aggregation tests as well as with a higher rate of major adverse cardiovascular events.^18,41 Our current study supported and extended the findings of these previous studies and showed a worse clinical outcome in patients treated with clopidogrel after acute ischemic stroke who carry CYP2C19*2 variant allele (genotype AA or AG) or interactive genotypes.

Furthermore, the P2Y12 receptor for clopidogrel¹⁹ and its effector, glycoprotein IIb/IIIa,²⁴ were the first pharmacogenetic targets and may be able to explain the biologic variability in response to this antiplatelet drug. Polymorphisms of P2RY12and GPIIIa were shown to be independent predictor of pharmacological response to clopidogrel,^42,43 although the ex vivo antiplatelet activity of clopidogrel was not associated with allelic variants of these 2 genes.^20,40,44 However, our current study did not show any association between polymorphisms of P2RY12 or GPIIIa and clinical outcomes in patients with acute IS treated with clopidogrel. Our current study did show that the interactions of P2Y12rs16863323, GPIIIars2317676, and CYP2C19 rs4244285 were independently associated with CR and with clopidogrel-induced adverse events during the first 6 months of treatment after acute IS. Our current data indicated that CR and its adverse clinical events may be multifactorial but were not caused by single gene polymorphisms. However, the nature of their interactions remains to be determined. One possible explanation for this may be that these 3 genes encode key enzymes to activate or modulate the pharmacokinetics, the pharmacodynamics, and the biologic activity of clopidogrel, which are the principles for patients to respond to clopidogrel. Further study will investigate the mechanisms by which these gene–gene interactions modify the biologic activity of clopidogrel.

Currently, there are no standardized treatment recommendations for CR. The dosing regime showed that the response to clopidogrel was beyond pharmacokinetics and CYP2C19*2 heterozygotes and required a daily dose of 225 mg to maintain “normal” platelet inhibition response, which triples the recommended dose of 75 mg.⁴⁵ Substitution of clopidogrel with another antiplatelet drug (like ticagrelor or prasugrel) is thought to be another regime and may help prevent the occurrence of vascular events.⁴⁶

However, our current study does have several potential limitations. For example, it did not include data on the assessment of plasma clopidogrel levels and its active metabolite. The current study may also have a possible bias due to its relatively small sample size and short follow-up period. Moreover, although we genotyped multiple known functional variants in clopidogrel-relevant genes in this cohort of patients, some rare functional variants may have been left undetected in this population; thus, we were not able to exclude their role in the regulation of CR. In addition, the exact pathological mechanism of these gene–gene interactions or clopidogrel activity remains unclear, although we found that gene–gene interactions were involved in clopidogrel metabolism and biologic activity. Future studies with a larger set of genetic variants, a multicenter, large sample size, and a longer follow-up period should be conducted to elucidate the full extent of gene–gene interaction effects on CR.

In conclusion, our current study showed that gene–gene interaction among CYP2C19*2(rs4244285), P2Y12 (rs16863323), and GPIIIa(rs2317676) were associated with CR and clopidogrel adverse clinical events as well.

Footnotes

Authors’ Note

Clinical Trial Registration Information : . Unique Identifier: ChiCTR-OCH-14004724.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by grants from the Deyang City Science and Technology Research Foundation (#2014SZ035) and the Scientific Research Foundation of Sichuan Provincial Health Department (#140025).

Supplemental Material

Supplementary material for this article is available online.

References

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.

Kernan

Ovbiagele

Black

; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339.

Sabatine

Cannon

Gibson

, Braunwald

; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189.

Yin

Miyata

. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128(4):307–316.

Silva

Almeida Junior

Neno

. Resistance to clopidogrel: prevalence and associate variables. Arq Bras Cardiol. 2012;99(6):1135–1141.

Rho

Shin

Kong

Kim

Lee

. Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc. 2011;50(1):40–44.

Sibbing

Morath

Stegherr

. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101(4):714–719.

10.

Simon

Verstuyft

Mary-Krause

; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375.

11.

Schror

. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med. 1998;3(3):247–251.

12.

Martinez-Quintana

Tugores

. Clopidogrel: a multifaceted affair. J Clin Pharmacol. 2015;55(1):1–9.

13.

Mega

Wiviott

. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–1319.

14.

Jia

Chen

Zhang

. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44(6):1717–1719.

15.

Mega

Wiviott

. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.

16.

Angiolillo

Fernandez-Ortiz

Bernardo

. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26(8):1895–1900.

17.

Suh

Koo

Zhang

. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174(12):1715–1722.

18.

Brandt

Iturria

. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436.

19.

Fontana

Dupont

Gandrille

. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108(8):989–995.

20.

Giusti

Gori

Marcucci

. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057–1064.

21.

Hulot

Bura

Villard

. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–2247.

22.

Taubert

von Beckerath

Grimberg

. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486–501.

23.

Trenk

Hochholzer

Fromm

. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925–1934.

24.

Angiolillo

Fernandez-Ortiz

Bernardo

. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15(1):89–93.

25.

Floyd

Ferro

. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446–457.

26.

Jaitner

Morath

Byrne

. No association of ABCB1 C3435 T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2012;5(1):82–88, s1–s2.

27.

Lau

Gurbel

Watkins

. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109(2):166–171.

28.

Tang

Wang

Zhang

. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435 T and PON1 Q192 R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(5):1103–1112.

29.

Lou

Chen

Yan

. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet. 2007;80(6):1125–1137.

30.

Han

Kim

Lee

. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol. 2007;57(2):96–102.

31.

Zhou

Lin

Chi

. Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. Int J Stroke. 2013;8(7):535–539.

32.

Zhou

Lin

Chi

Han

. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50 T and COX-2 G765C. J Atheroscler Thromb. 2013;20(1):65–72.

33.

Liao

Zhang

Wang

. Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations. J Atheroscler Thromb. 2015;22(11):1148–1157.

34.

Zhang

Wang

Liao

Lin

Chi

. CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke. Gene. 2015;565(1):85–89.

35.

Ingelman-Sundberg

Sim

Gomez

Rodriguez-Antona

. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526.

36.

Piper

Aronson

Ziegler

. Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. Technol Eval Cent Assess Program Exec Summ. 2004;19(9):1–2.

37.

Sim

Ingelman-Sundberg

. The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol. 2006;320(1):183–191.

38.

Clarke

Waskell

. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31(1):53–59.

39.

Priyadharsini

Shewade

Subraja

. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. Mol Biol Rep. 2014;41(11):7265–7271.

40.

Smith

Judge

Peters

. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets. 2006;17(4):250–258.

41.

Wallentin

James

Storey

; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320–1328.

42.

Galic

Vrbanic

Kapitanovic

. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation. Coll Antropol. 2013;37(2):491–498.

43.

Staritz

Kurz

Stoll

Giannitsis

Katus

Ivandic

. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y 12-ADP receptor gene. Int J Cardiol. 2009;133(3):341–345.

44.

Lev

Patel

Guthikonda

Lopez

Bray

Kleiman

. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007;119(3):355–360.

45.

Mega

Hochholzer

Frelinger

III . Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–2228.

46.

Mehta

Tanguay

Eikelboom

; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233–1243.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB